What Happened?

Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 94.9% in the afternoon session after the company announced that its Phase 3 trial (ROSELLA) met its goal of improving progression-free survival and overall survival in treating resistant ovarian cancer with a new therapy (a combination of Relacorilant and Nab-paclitaxel). 

In a press release, CORT said the mix worked better than chemotherapy alone using Nab-paclitaxel and didn't cause more side effects. The results pointed to Relacorilant as a strong choice for people with few treatment paths. Corcept planned to file for approval in the U.S. and Europe by the end of the year, which is a key move towards commercializing the drug. 

Overall, the data validated Corcept's cancer treatment result and showed that Relacorilant could stand out as a new cancer therapy.

Is now the time to buy Corcept? Access our full analysis report here, it’s free.

What The Market Is Telling Us

Corcept’s shares are very volatile and have had 21 moves greater than 5% over the last year. But moves this big are rare even for Corcept and indicate this news significantly impacted the market’s perception of the business.

Corcept is up 114% since the beginning of the year, and at $106.90 per share, has set a new 52-week high. Investors who bought $1,000 worth of Corcept’s shares 5 years ago would now be looking at an investment worth $8,981.

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. We prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.